Ryuichiro Atarashi

Dr. Ryuichiro Atarashi

Division of Microbiology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JKJae-Il Kim
Jae-Il Kim
ICIgnazio Cali
Ignazio Cali
KSKrystyna Surewicz
Krystyna Surewicz
Qingzhong KongQingzhong Kong
Qingzhong Kong
GRGregory J. Raymond
Gregory J. Raymond
WSWitold K. Surewicz
Witold K. Surewicz
Transmissible spongiform encephalopathies (TSEs) are a group of neurodegenerative diseases that are associated with the conformational conversion of a normal prion protein, PrP(C), to a misfolded aggregated form, PrP(Sc). The protein-only hypothesis asserts that PrP(Sc) itself represents the infectious TSE agent. Although this model is supported by rapidly growing experimental data, unequivocal proof has been elusive. The protein misfolding cyclic amplification reactions have been recently shown to propagate prions using brain-derived or recombinant prion protein, but only in the presence of additional cofactors such as nucleic acids and lipids. Here, using a protein misfolding cyclic amplification variation, we show that prions causing transmissible spongiform encephalopathy in wild-type hamsters can be generated solely from highly purified, bacterially expressed recombinant hamster prion protein without any mammalian or synthetic cofactors (other than buffer salts and detergent). These findings provide strong support for the protein-only hypothesis of TSE diseases, as well as argue that cofactors such as nucleic acids, other polyanions, or lipids are non-obligatory for prion protein conversion to the infectious form.

27 January 2022 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
RARyuichiro Atarashi
Ryuichiro Atarashi

27 April 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
YMYukiko Miyazaki
Yukiko Miyazaki
TITakeshi Ishikawa
Takeshi Ishikawa
Yuji KamatariYuji Kamatari
Yuji Kamatari
TNTakehiro Nakagaki
Takehiro Nakagaki
HTHanae Takatsuki
Hanae Takatsuki
RARyuichiro Atarashi
Ryuichiro Atarashi

Verified
Journal Article
Open access
PDF file
KUKeiji Uchiyama
Keiji Uchiyama
HHHideyuki Hara
Hideyuki Hara
JCJunji Chida
Junji Chida
APAgriani Dini Pasiana
Agriani Dini Pasiana
MIMorikazu Imamura
Morikazu Imamura
SSSuehiro Sakaguchi
Suehiro Sakaguchi
Prion diseases are a group of fatal neurodegenerative disorders caused by accumulation of proteinaceous infectious particles, or prions, which mainly consist of the abnormally folded, amyloidogenic prion protein, designated PrPSc. PrPSc is produced through conformational conversion of the cellular isoform of prion protein, PrPC, in the brain. To date, no effective therapies for prion diseases have been developed. In this study, we incidentally noticed that mouse neuroblastoma N2a cells persistently infected with 22L scrapie prions, termed N2aC24L1-3 cells, reduced PrPSc levels when cultured in advanced Dulbecco’s modified eagle medium (DMEM) but not in classic DMEM. PrPC levels remained unchanged in prion-uninfected parent N2aC24 cells cultured in advanced DMEM. These results suggest that advanced DMEM may contain an anti-prion compound(s). We then successfully identified ethanolamine in advanced DMEM has an anti-prion activity. Ethanolamine reduced PrPSc levels in N2aC24L1-3 cells, but not PrPC levels in N2aC24 cells. Also, oral administration of ethanolamine through drinking water delayed prion disease in mice intracerebrally inoculated with RML scrapie prions. These results suggest that ethanolamine could be a new anti-prion compound.

Verified
Journal Article
Open access
PDF file
KUKeiji Uchiyama
Keiji Uchiyama
HMHironori Miyata
Hironori Miyata
YYYoshitaka Yamaguchi
Yoshitaka Yamaguchi
MIMorikazu Imamura
Morikazu Imamura
MOMariya Okazaki
Mariya Okazaki
SSSuehiro Sakaguchi
Suehiro Sakaguchi
Conformational conversion of the cellular prion protein, PrPC, into the abnormally folded isoform, PrPSc, is a key pathogenic event in prion diseases. However, the exact conversion mechanism remains largely unknown. Transgenic mice expressing PrP with a deletion of the central residues 91–106 were generated in the absence of endogenous PrPC, designated Tg(PrP∆91–106)/Prnp0/0 mice and intracerebrally inoculated with various prions. Tg(PrP∆91–106)/Prnp0/0 mice were resistant to RML, 22L and FK-1 prions, neither producing PrPSc∆91–106 or prions in the brain nor developing disease after inoculation. However, they remained marginally susceptible to bovine spongiform encephalopathy (BSE) prions, developing disease after elongated incubation times and accumulating PrPSc∆91–106 and prions in the brain after inoculation with BSE prions. Recombinant PrP∆91-104 converted into PrPSc∆91–104 after incubation with BSE-PrPSc-prions but not with RML- and 22L–PrPSc-prions, in a protein misfolding cyclic amplification assay. However, digitonin and heparin stimulated the conversion of PrP∆91–104 into PrPSc∆91–104 even after incubation with RML- and 22L-PrPSc-prions. These results suggest that residues 91–106 or 91–104 of PrPC are crucially involved in prion pathogenesis in a strain-dependent manner and may play a similar role to digitonin and heparin in the conversion of PrPC into PrPSc.

13 May 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HTHanae Takatsuki
Hanae Takatsuki
MIMorikazu Imamura
Morikazu Imamura
TMTsuyoshi Mori
Tsuyoshi Mori
RARyuichiro Atarashi
Ryuichiro Atarashi
Each prion strain has its own characteristics and the efficacy of anti-prion drugs varies. Screening of prion disease therapeutics is typically evaluated by measuring amounts of protease-resistant prion protein (PrP-res). However, it remains unclear whether such measurements correlate with seeding activity, which is evaluated by real-time quaking-induced conversion (RT-QuIC). In this study, the effects of anti-prion compounds pentosan polysulfate (PPS), Congo red, and alprenolol were measured in N2a58 cells infected with Fukuoka-1 (FK1) or 22L strain. The compounds abolished PrP-res and seeding activity, except for N2a58/FK1 treated with PPS. Interestingly, the seeding activity of N2a58/FK1, which was reduced in the presence of PPS, was not lost and remained at low levels. However, upon removal of PPS, both were gradually restored to their original levels. These results indicate that low-level persistent prion infection keeping measurable seeding activity is induced by PPS in a strain-dependent manner. Furthermore, for protein misfolding cyclic amplification (PMCA), the anti-prion effect of PPS decreased in FK1 compared to 22L, suggesting that the differences occur at the level of the direct conversion. Our findings demonstrate that the advantages of RT-QuIC and PMCA can be exploited for more accurate assessment of therapeutic drug screening, reflecting strain differences.